Dr. Garon Discusses the CheckMate-384 Study in NSCLC

Video

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non—small cell lung cancer (NSCLC) during the 2018 European Lung Cancer Congress, which is a joint collaboration between ESMO and the IASLC.

CheckMate-384 is a phase IIIb/IV dose-frequency optimization trial in progress of nivolumab (Opdivo) in advanced or metastatic NSCLC. The currently approved dosing of nivolumab in this population is 240 mg every 2 weeks until progression or discontinuation due to toxicity. This study is investigating this regimen randomized against 480 mg every 4 weeks.

Garon says that in an ideal world, patients would not have to come into the clinic every 2 weeks for treatment. This trial is aiming to see if this higher, less frequent dosing schedule will be as effective as what is currently done in practice. Additionally, reducing dose frequency could optimize convenience during long-term nivolumab therapy, which could improve quality of life for patients.

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Raj Singh, MD
Arya Amini, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital